GD2/PSMA CAR-T therapy for hard-to-remove metastatic cancers
Part of Cancer clinical trials.
This early-phase study tests a custom immune-cell treatment (CAR-T) that targets two tumor markers called GD2 and PSMA. It may help people whose cancer is advanced, cannot be removed with surgery, and has the right marker pattern in their tumor tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has already had standard first treatment, and it cannot be fully removed by surgery (it’s metastatic, recurring, or still growing).
- Your tumor tissue must test positive for GD2 or PSMA using lab staining of the tumor (immunohistochemistry or flow cytometry).
- You are between 1 and 75 years old, weigh at least 10 kg, and are expected to live at least 8 weeks.
- You must have recovered from prior side effects: any prior severe non-blood side effects (grade 3–4) should be back to mild (grade 2 or less).
- Timing rules matter: avoid certain cancer treatments for specific time windows (including at least 4 weeks since monoclonal antibody, and at least 1 week after radiation).
- Your body must be healthy enough for treatment: adequate heart, oxygen levels, liver, kidney, and blood counts (based on lab tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a genetically engineered CAR T-cell treatment called 4SCAR-GD2 for certain solid tumors that have a marker called GD2. It may help shrink tumors that have returned, spread, or can’t be removed with surgery after standard treatment.
This trial tests a new type of immune cell therapy (CAR T cells) that targets the CD276 protein found on some solid tumors. It is for people whose cancer has not responded to standard treatment or has returned.
This trial tests a new type of immune cell (CAR T) made from healthy donors to fight solid tumors that have not responded to other treatments. It may be an option for people with certain cancers that show a protein called PD-L1.
This early-phase study tests a lab-made immune cell treatment (CAR-T) that targets tumor markers called GD2 and CD70. It is for people whose cancer has spread or returned and cannot be removed by surgery, to see if the treatment can work and how safe it is.
This trial tests a personalized CAR-T cell therapy that targets three specific markers (GD2, PSMA, and CD276) on neuroblastoma cells. It is for patients whose cancer has come back or not responded to standard treatment.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.